General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(SIGNIFICANT), Bristol-Myers Squibb Company (MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Health [at] Scale(MODEST) RESEARCH/RESEARCH GRANTS: Eisai(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Amgen Inc.(SIGNIFICANT)

View Full Disclosure